Actions of glucagon-like peptide-1 receptor ligands in the gut

Research output: Contribution to journal › Review › Research › peer-review

Standard

Actions of glucagon-like peptide-1 receptor ligands in the gut. / Holst, Jens Juul; Andersen, Daniel Bjørklund; Grunddal, Kaare Villum.

In: British Journal of Pharmacology, Vol. 179, No. 4, 2022, p. 727-742.

Research output: Contribution to journal › Review › Research › peer-review

Harvard

Holst, JJ, Andersen, DB & Grunddal, KV 2022, 'Actions of glucagon-like peptide-1 receptor ligands in the gut', British Journal of Pharmacology, vol. 179, no. 4, pp. 727-742. https://doi.org/10.1111/bph.15611

APA

Holst, J. J., Andersen, D. B., & Grunddal, K. V. (2022). Actions of glucagon-like peptide-1 receptor ligands in the gut. British Journal of Pharmacology, 179(4), 727-742. https://doi.org/10.1111/bph.15611

Vancouver

Holst JJ, Andersen DB, Grunddal KV. Actions of glucagon-like peptide-1 receptor ligands in the gut. British Journal of Pharmacology. 2022;179(4):727-742. https://doi.org/10.1111/bph.15611

Author

Holst, Jens Juul ; Andersen, Daniel Bjørklund ; Grunddal, Kaare Villum. / Actions of glucagon-like peptide-1 receptor ligands in the gut. In: British Journal of Pharmacology. 2022 ; Vol. 179, No. 4. pp. 727-742.

Bibtex

@article{003d4354dd034ae39697ef921031b2ad,
title = "Actions of glucagon-like peptide-1 receptor ligands in the gut",
abstract = "The incretin hormone glucagon-like peptide-1 (GLP-1) is inactivated by the enzyme dipeptidyl peptidase-4 even before it leaves the gut, but it seems to act predominantly via activation of intestinal sensory neurons expressing GLP-1 receptors. Thus, activation of vagal afferents is probably responsible for its effects on appetite and food intake, gastrointestinal secretion and motility, and pancreatic endocrine secretion. However, GLP-1 receptors are widely expressed in the gastrointestinal (GI) tract, including epithelial cells in the stomach, and the Brunner glands, in endocrine cells of the gut epithelium, and on mucosal lymphocytes. In this way, GLP-1 may have important local actions of epithelial protection and endocrine signalling and may interact with the immune system. We review the formation and release of GLP-1 from the endocrine L cells and its fate after release and describe the localization of its receptor throughout the GI tract and discuss its direct or indirect actions in the GI tract.",
author = "Holst, {Jens Juul} and Andersen, {Daniel Bj{\o}rklund} and Grunddal, {Kaare Villum}",
note = "{\textcopyright} 2021 The British Pharmacological Society. Themed Issue: GLP1 receptor ligands (BJP 75th Anniversary)",
year = "2022",
doi = "10.1111/bph.15611",
language = "English",
volume = "179",
pages = "727--742",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
publisher = "Wiley",
number = "4",

}

RIS

TY - JOUR

T1 - Actions of glucagon-like peptide-1 receptor ligands in the gut

AU - Holst, Jens Juul

AU - Andersen, Daniel Bjørklund

AU - Grunddal, Kaare Villum

N1 - © 2021 The British Pharmacological Society. Themed Issue: GLP1 receptor ligands (BJP 75th Anniversary)

PY - 2022

Y1 - 2022

N2 - The incretin hormone glucagon-like peptide-1 (GLP-1) is inactivated by the enzyme dipeptidyl peptidase-4 even before it leaves the gut, but it seems to act predominantly via activation of intestinal sensory neurons expressing GLP-1 receptors. Thus, activation of vagal afferents is probably responsible for its effects on appetite and food intake, gastrointestinal secretion and motility, and pancreatic endocrine secretion. However, GLP-1 receptors are widely expressed in the gastrointestinal (GI) tract, including epithelial cells in the stomach, and the Brunner glands, in endocrine cells of the gut epithelium, and on mucosal lymphocytes. In this way, GLP-1 may have important local actions of epithelial protection and endocrine signalling and may interact with the immune system. We review the formation and release of GLP-1 from the endocrine L cells and its fate after release and describe the localization of its receptor throughout the GI tract and discuss its direct or indirect actions in the GI tract.

AB - The incretin hormone glucagon-like peptide-1 (GLP-1) is inactivated by the enzyme dipeptidyl peptidase-4 even before it leaves the gut, but it seems to act predominantly via activation of intestinal sensory neurons expressing GLP-1 receptors. Thus, activation of vagal afferents is probably responsible for its effects on appetite and food intake, gastrointestinal secretion and motility, and pancreatic endocrine secretion. However, GLP-1 receptors are widely expressed in the gastrointestinal (GI) tract, including epithelial cells in the stomach, and the Brunner glands, in endocrine cells of the gut epithelium, and on mucosal lymphocytes. In this way, GLP-1 may have important local actions of epithelial protection and endocrine signalling and may interact with the immune system. We review the formation and release of GLP-1 from the endocrine L cells and its fate after release and describe the localization of its receptor throughout the GI tract and discuss its direct or indirect actions in the GI tract.

U2 - 10.1111/bph.15611

DO - 10.1111/bph.15611

M3 - Review

C2 - 34235727

VL - 179

SP - 727

EP - 742

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

IS - 4

ER -

ID: 275887163